RU2224258C2 - Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12 - Google Patents

Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12 Download PDF

Info

Publication number
RU2224258C2
RU2224258C2 RU2001132334/15A RU2001132334A RU2224258C2 RU 2224258 C2 RU2224258 C2 RU 2224258C2 RU 2001132334/15 A RU2001132334/15 A RU 2001132334/15A RU 2001132334 A RU2001132334 A RU 2001132334A RU 2224258 C2 RU2224258 C2 RU 2224258C2
Authority
RU
Russia
Prior art keywords
concentration
vitamin
analyte
risk
pgi
Prior art date
Application number
RU2001132334/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2001132334A (ru
Inventor
Пентти СИППОНЕН (FI)
Пентти Сиппонен
Матти ХЯРКЕНЕН (FI)
Матти Хяркенен
Осмо СУОВАНИЕМИ (FI)
Осмо Суованиеми
Эрик ФОРСБЛОМ (FI)
Эрик ФОРСБЛОМ
Original Assignee
Биохит Ойй
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биохит Ойй filed Critical Биохит Ойй
Publication of RU2001132334A publication Critical patent/RU2001132334A/ru
Application granted granted Critical
Publication of RU2224258C2 publication Critical patent/RU2224258C2/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
RU2001132334/15A 1999-04-30 2000-04-28 Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12 RU2224258C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI990991A FI990991L (fi) 1999-04-30 1999-04-30 Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi
FI990991 1999-04-30

Publications (2)

Publication Number Publication Date
RU2001132334A RU2001132334A (ru) 2003-08-27
RU2224258C2 true RU2224258C2 (ru) 2004-02-20

Family

ID=8554566

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001132334/15A RU2224258C2 (ru) 1999-04-30 2000-04-28 Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12

Country Status (12)

Country Link
EP (1) EP1173764B1 (enExample)
JP (1) JP2002543430A (enExample)
CN (1) CN1353816A (enExample)
AT (1) ATE319088T1 (enExample)
AU (1) AU4299700A (enExample)
DE (1) DE60026285T2 (enExample)
DK (1) DK1173764T3 (enExample)
ES (1) ES2258453T3 (enExample)
FI (1) FI990991L (enExample)
PT (1) PT1173764E (enExample)
RU (1) RU2224258C2 (enExample)
WO (1) WO2000067029A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2413940C2 (ru) * 2009-02-02 2011-03-10 Государственное образовательное учреждение высшего профессионального образования Воронежская государственная технологическая академия Способ определения витамина b12 в водных растворах

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20010019L (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
FI20065542A0 (fi) * 2006-09-01 2006-09-01 Biohit Oyj Menetelmä ja näytteenottopakkaus vatsan limakalvon tilan arvioimiseksi

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015456A1 (en) * 1994-11-16 1996-05-23 Locus Genex Oy Method for screening the risk of gastric cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015456A1 (en) * 1994-11-16 1996-05-23 Locus Genex Oy Method for screening the risk of gastric cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Штульман Д.Р., Мельничук B.П. Нервные болезни. Справочник практического врача. - М.: Баян, 1994, с.402-425. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2413940C2 (ru) * 2009-02-02 2011-03-10 Государственное образовательное учреждение высшего профессионального образования Воронежская государственная технологическая академия Способ определения витамина b12 в водных растворах

Also Published As

Publication number Publication date
JP2002543430A (ja) 2002-12-17
ATE319088T1 (de) 2006-03-15
FI990991A7 (fi) 2000-10-31
PT1173764E (pt) 2006-06-30
DE60026285T2 (de) 2006-11-09
CN1353816A (zh) 2002-06-12
WO2000067029A1 (en) 2000-11-09
DE60026285D1 (de) 2006-04-27
AU4299700A (en) 2000-11-17
FI990991A0 (fi) 1999-04-30
EP1173764A1 (en) 2002-01-23
ES2258453T3 (es) 2006-09-01
FI990991L (fi) 2000-10-31
DK1173764T3 (da) 2006-05-08
EP1173764B1 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
US20070212742A1 (en) Determination of a Midregional Proadrenomedullin Partial Peptide in Biological Fluids for Diagnostic Purposes, and Immunoassays for Carrying out Such a Determination
CA2360219A1 (en) Method for detecting alzheimer's disease
WO2020146497A1 (en) An electrochemiluminescence elisa for ps129-a-synuclein
KR100394940B1 (ko) 간 질환 진단을 위한 혈중 아사이알로당단백질양의측정방법 및 측정용 킷트
Sheabar et al. Quantitative analysis of aflatoxin-albumin adducts
US20040229300A1 (en) Zinc-based screening test and kit for early diagnosis of prostate cancer
RU2224258C2 (ru) Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12
JP4242499B2 (ja) ホスホリルコリンを用いたｃｒｐの測定方法
Symons et al. An evaluation of a fluorescence polarization immunoassay of thyroxin and thyroxin-uptake.
CN107002017B (zh) 疏水性半抗原分析物的精确测定测量
RU2247389C2 (ru) Способ идентификации индивидуума с риском сосудистого и ракового заболевания
EP0965043B1 (en) Detection of cardiac muscle necrosis by immunoassay and appropriate antibodies therefor
WO2011158769A1 (ja) 非アルコール性脂肪肝炎検出および／または鑑別用マーカー、非アルコール性脂肪肝炎を検出および／または鑑別する方法およびそれらに用いるキット
Tateishi et al. Stability of bombesin in serum, plasma, urine, and culture media.
JP2003508059A5 (enExample)
JP5048207B2 (ja) 敗血症状態の発症および存在を決定するための装置及び方法
Tomokuni et al. Comparison between the fluorometric HPLC method and the conventional method for determining urinary δ-aminolevulinic acid and coproporphyrin as indices of lead exposure
Panteghini Clinical and analytical performance of automated immunochemiluminometric assays for determination of cardiac markers in serum
Attia et al. A highly selective and sensitive spectrofluorimetric method for the assessment of 3-nitrotyrosine in serum using (Eu (TTA) 3 Phen) photo probe
Viberg Evaluation of methods for proinsulin quantification and the proinsulin: C-peptide ratio in type 1 diabetes prediction
WO1990011526A1 (en) Cancer diagnosis
Chen et al. B-259 RNase L Deficiency Enhances Renal Self-Repair Following Nephrotoxin-induced Acute Kidney Injury via EGFR/AKT Activation and Apoptosis Inhibition
AU2001280912A1 (en) Apparatus and method for determining the onset and presence of sepsis conditions
Hurwitz et al. Influence of sodium intake on the reliability of active renin as a measure of the renin-angiotensin system in essential hypertension
JP2016148619A (ja) 尿中のアクロレイン代謝物及びクレアチニンを指標とする認知機能障害の検査方法